140 related articles for article (PubMed ID: 17119488)
21. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Taylor DM; Wright T; Libretto SE;
J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
[TBL] [Abstract][Full Text] [Related]
22. [Pro and contra: basic precedence of atypical neuroleptics].
Naber D; Dose M
Psychiatr Prax; 2005 May; 32(4):163-6. PubMed ID: 15852207
[No Abstract] [Full Text] [Related]
23. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
24. Cost analysis of risperidone long-acting injection in the treatment of schizophrenia and schizoaffective disorders in Hong Kong: an approach using generalised estimating equations.
Wu DB; Lee EH; Chung WS; Chow DP; Lee VW; Wong MC; Lee KK
Psychiatry Res; 2013 Dec; 210(3):745-50. PubMed ID: 24012164
[TBL] [Abstract][Full Text] [Related]
25. Clozapine and hospitalization.
Rosenheck R; Charney D; Cramer J
Psychiatr Serv; 1999 Jan; 50(1):114-6. PubMed ID: 9890595
[No Abstract] [Full Text] [Related]
26. [Cost-effectiveness of Antipsychotics in the Maintenance Treatment of Schizophrenia in Colombia].
Quitian Reyes H; Arciniegas Barrera JA; Bohórquez Peñaranda A; Gómez Restrepo C
Rev Colomb Psiquiatr; 2016; 45(2):67-74. PubMed ID: 27132755
[TBL] [Abstract][Full Text] [Related]
27. Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.
Kopala L; Smith G; Malla A; Williams R; Love L; Talling D; Balshaw R
Acta Psychiatr Scand Suppl; 2006; (430):29-39. PubMed ID: 16542323
[TBL] [Abstract][Full Text] [Related]
28. [Cost-effectiveness study of olanzapine pamoate: Mirror-image analysis after one year].
Potaufeu J; Langrée B; Drapier D; Burgot G; Marie N
Encephale; 2019 Jun; 45(3):232-238. PubMed ID: 30579574
[TBL] [Abstract][Full Text] [Related]
29. The NIMH-CATIE Schizophrenia Study: what did we learn?
Lieberman JA; Stroup TS
Am J Psychiatry; 2011 Aug; 168(8):770-5. PubMed ID: 21813492
[No Abstract] [Full Text] [Related]
30. Did CATIE influence antipsychotic use?
Citrome L; Jaffe A; Martello D; Allingham B; Levine J
Psychiatr Serv; 2008 May; 59(5):476. PubMed ID: 18451000
[No Abstract] [Full Text] [Related]
31. Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia.
Barnett PG; Scott JY; Krystal JH; Rosenheck RA;
J Clin Psychiatry; 2012 May; 73(5):696-702. PubMed ID: 22697193
[TBL] [Abstract][Full Text] [Related]
32. Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia.
Ascher-Svanum H; Nyhuis AW; Faries DE; Ball DE; Kinon BJ
BMC Psychiatry; 2010 Jan; 10():11. PubMed ID: 20109170
[TBL] [Abstract][Full Text] [Related]
33. What explains the diffusion of treatments for mental illness?
Drake R; Skinner J; Goldman HH
Am J Psychiatry; 2008 Nov; 165(11):1385-92. PubMed ID: 18981070
[No Abstract] [Full Text] [Related]
34. Formulary decisions and health economics.
Glazer WM
J Clin Psychiatry; 1998; 59 Suppl 19():23-9. PubMed ID: 9847049
[TBL] [Abstract][Full Text] [Related]
35. Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
Rosenheck RA
Arch Gen Psychiatry; 2006 Oct; 63(10):1074-6. PubMed ID: 17015809
[No Abstract] [Full Text] [Related]
36. Management of chronic psychotic ambulatory outpatients.
Petty RG
J Clin Psychiatry; 1998; 59 Suppl 19():30-5. PubMed ID: 9847050
[TBL] [Abstract][Full Text] [Related]
37. Economic consequences of alternative medication strategies in first episode non-affective psychosis.
Stant AD; TenVergert EM; Wunderink L; Nienhuis FJ; Wiersma D
Eur Psychiatry; 2007 Sep; 22(6):347-53. PubMed ID: 17418538
[TBL] [Abstract][Full Text] [Related]
38. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.
Druais S; Doutriaux A; Cognet M; Godet A; Lançon C; Levy P; Samalin L; Guillon P
Pharmacoeconomics; 2016 Apr; 34(4):363-91. PubMed ID: 26883132
[TBL] [Abstract][Full Text] [Related]
39. Combination therapy: is clinical practice leading the way?
Welch R; Snaterse M
J Clin Psychiatry; 2003 Jan; 64(1):94; author reply 94-6. PubMed ID: 12590630
[No Abstract] [Full Text] [Related]
40. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
Marcus SC; Olfson M
Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
